|
|
Nursing Management of Oral Mucositis
STATEMENT OF NEED
Oral mucositis (OM) is the inflammation of oral mucosa resulting from cancer therapy and manifesting as atrophy, swelling, erythema, and ulceration (Oronsky et al, 2018). Patients with OM may experience moderate-to-severe pain, difficulty speaking, difficulty eating and drinking, and ulcerations characterized by submucosal hemorrhaging and infection (Bolton, 2021). Due to these crippling effects, OM is considered one of the most debilitating toxicities of cancer therapy (W... |
|
|
Nursing Management of Cancer Treatment Induced Cardiotoxicity
STATEMENT OF NEED
Several studies reveal that certain cancer therapies adversely affect the heart and lead to various types of injuries, which often result in death. Adverse cardiac effects may occur immediately after cessation of therapy or, in some cases, years after the therapy has been discontinued. Often the cardiotoxicity presents in subtle ways, and a lack of awareness results in high morbidity and mortality. It is important for oncology nurses to be aware of current advances in the ... |
|
|
Cleveland Clinic 18th Annual Obesity Summit
Cleveland Clinic’s 18th Annual Obesity Summit is designed for a diverse mix of health care practitioners interested in innovative solutions and new strategies to care for patients with obesity. Causes of obesity and diabetes, preventive strategies, and therapeutic management approaches are discussed throughout this activity, with special focus place on health disparities, lifestyle, diet & exercise, surgical treatment, medication, patient-centered treatment, complications and weight recu... |
|
|
Advances in™ Beta-Thalassemia: The Evolving Therapeutic Landscape
Target Audience
This educational activity is directed toward hematologists and hematologist-oncologists, as well as pediatricians, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with beta-thalassemia.
Program Overview
This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of β-thalassemia, with a forward-looking perspective on how new and novel agents might imp... |
|